



Extended Follow-up of Botensilimab plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer without Active Liver Metastases

Benjamin L. Schlechter¹, Marwan G. Fakih², Apostolia M. Tsimberidou³, Andrea J. Bullock⁴, Agustin Pimentel⁵, Sunil Sharma⁶, Heinz-Josef Lenz⁷, Michael S. Gordon⁶, Ghassan K. Abou-Alfa^{8,9,10}, Thomas U. Marron¹¹, Robert W. Lentz¹², Wells Messersmith¹², Ian Chau¹³, Bruno Bockorny⁴, Dhan Chand¹⁴, Manushak Avagyan¹⁴, Wei Wu¹⁴, Benny Johnson¹⁴, Joseph E. Grossman¹⁴, Steven J. O'Day¹⁴, Anthony B. El-Khoueiry⁷, and Neil H. Segal^{8,9}

ABSTRACT

Purpose: Microsatellite-stable metastatic colorectal cancer (MSS mCRC) has limited treatment options and responds poorly to conventional immunotherapy. We report extended follow-up results from a fully enrolled, phase Ib cohort evaluating botensilimab [BOT; Fc-enhanced anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)] plus balstilimab [BAL; anti-programmed cell death protein 1 (PD-1)] in patients with MSS mCRC and no active liver metastases (NLM).

Patients and Methods: Patients received BOT 1 or 2 mg/kg every 6 weeks plus BAL 3 mg/kg every 2 weeks up to 2 years or until progression or unacceptable toxicity. The primary objective was safety/tolerability. Efficacy endpoints included objective response rate (ORR), duration of response (DOR), and progression-free survival (PFS); overall survival (OS) was exploratory. Patients with prior regorafenib, trifluridine/tipiracil ± bevacizumab, or fruquintinib ("late-line exposed") were analyzed post hoc.

Results: As of December 13, 2025, 123 patients were treated [median follow-up, 20.2 months (range, 0.7–62.3)]. The median prior lines was 3 (range, 1–10; 67% had ≥3 prior lines). The most common treatment-related adverse events were diarrhea (39%; grade ≥3, 8%) and fatigue (37%; grade ≥3, 2%). The ORR was 21% [95% confidence interval (CI), 14–29]. The median DOR was not reached (NR; 95% CI, 7.3–NR), the median PFS was 4.0 months (95% CI, 2.8–4.1), and the median OS was 21.2 months [95% CI, 16.2–23.8; 36-month OS, 33% (95% CI, 24–43)]. Efficacy was consistent in late line-exposed patients [*n* = 37; ORR, 22% (95% CI, 10–38); median OS, 16.2 months (95% CI, 9.7–31.3)].

Conclusions: BOT + BAL demonstrated durable responses, long-term survival, and manageable safety in previously treated MSS mCRC NLM, including in late line-exposed patients. These results support further evaluation.

Introduction

Colorectal cancer is the third most common type of cancer worldwide, with approximately 1.9 million new diagnoses in 2022 (1). In the United States, approximately 154,300 people were diagnosed in 2025, with 52,900 estimated deaths from the disease (2). Despite declining mortality for most major cancers in individuals <50 years of age in the United States, early-onset colorectal cancer is now the leading cause of cancer-related death in this age group (3). Nearly 95% of patients with advanced colorectal cancer have microsatellite-stable (MSS)/mismatch repair-proficient (pMMR) disease, which is associated with limited effective treatment options and substantial unmet need (4, 5).

Survival rates in metastatic colorectal cancer (mCRC) have increased modestly with the use of combination chemotherapies plus treatments targeting vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR; refs. 6–10). After failure of such therapies, standard later-line salvage therapies include regorafenib, trifluridine/tipiracil ± bevacizumab, and fruquintinib, which have demonstrated limited clinical benefit in randomized phase III trials (predominantly MSS populations), with objective response rates (ORR) of 1% to 6% and median overall survival (OS) of approximately 6 to 11 months (11–16). Even when limiting these study populations to patients with no active liver metastases (NLM), the ORR remains poor (3%–8%), as does median OS (approximately 12–14 months; refs. 17–19). This highlights that although patients with NLM have better prognoses than patients with active liver metastases

¹Dana-Farber Cancer Institute, Boston, Massachusetts. ²City of Hope Comprehensive Cancer Center, Duarte, California. ³University of Texas, MD Anderson Cancer Center, Houston, Texas. ⁴Beth Israel Deaconess Medical Center, Boston, Massachusetts. ⁵University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida. ⁶HonorHealth Research Institute, Scottsdale, Arizona. ⁷University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California. ⁸Memorial Sloan Kettering Cancer Center, New York, New York. ⁹Weill Cornell Medical College, New York, New York. ¹⁰Trinity College Dublin, Dublin, Ireland. ¹¹Mount Sinai, Tisch Cancer Center, New York, New York. ¹²University of Colorado Cancer Center, Aurora, Colorado. ¹³The Royal Marsden Hospital, London, United Kingdom. ¹⁴Agenus Inc., Lexington, Massachusetts.

B.L. Schlechter, M.G. Fakih, and A.M. Tsimberidou share joint first authorship.

A.B. El-Khoueiry and N.H. Segal share joint last authorship.

Clinical trial registration ID: NCT03860272 (C-800-01 Trial)

Corresponding Author: Benjamin L. Schlechter, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215. E-mail: benjamin_schlechter@dfci.harvard.edu

Clin Cancer Res 2026;XX:XX-XX

doi: 10.1158/1078-0432.CCR-26-1610

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.

©2026 The Authors; Published by the American Association for Cancer Research

Translational Relevance

We report extended safety and efficacy follow-up of botensilimab [BOT; multifunctional Fc-enhanced anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)] plus balstilimab [BAL; anti-programmed cell death protein 1 (PD-1)] in a fully enrolled phase Ib cohort of patients with microsatellite-stable metastatic colorectal cancer and no active liver metastases (MSS mCRC NLM), including a late line-exposed subgroup. BOT + BAL induced deep/durable responses in heavily pretreated MSS mCRC NLM, a population in which durable survival >18 months remains uncommon. With a confirmed objective response rate of 21%, sustained survival beyond 2 and 3 years, consistent activity in late line-exposed patients, and a manageable safety profile, this regimen represents a potentially important advance in the treatment of MSS mCRC NLM. Clinical activity occurred independent of programmed cell death ligand 1 (PD-L1) or tumor mutational burden status supporting BOT's FcγR-dependent mechanism. These findings underscore the potential of BOT + BAL to generate meaningful antitumor activity in immunologically "cold" and immune checkpoint inhibitor-refractory tumors and support phase III evaluation.

(19), patients with NLM remain a population with high unmet need. Altogether, durable survival in MSS mCRC remains uncommon, with 18-month survival observed in a minority of late-line patients and ≥24-month survival rarely reported.

Immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1/programmed cell death ligand 1 [PD-(L)1] have demonstrated notable efficacy in several cancers, with durable survival plateaus and event-free survival observed in a proportion of patients (20, 21). In mCRC, however, meaningful clinical benefit from ICI has historically been limited to the small subset of patients (about 5%) with microsatellite instability-high/mismatch repair-deficient disease (4, 22, 23). In contrast, MSS mCRC has historically been refractory to ICI. Dual PD-(L)1 and CTLA-4 checkpoint blockade in MSS mCRC has demonstrated ORR of 1% (durvalumab + tremelimumab) and 5% (nivolumab + ipilimumab; refs. 24, 25). Thus, no ICI regimen has yet achieved meaningful clinical benefit in MSS mCRC.

The limited efficacy with conventional ICI observed in MSS mCRC likely reflects its poor immunogenicity and "cold" tumor microenvironment, defined by low CD8⁺ T-cell infiltration, minimal immune activation, and the presence of suppressive myeloid and regulatory T-cell (Treg) populations, which are all hallmarks of dysfunctional adaptive T-cell immunity (26). Botensilimab (BOT) is a multifunctional Fc-enhanced anti-CTLA-4 antibody that, unlike conventional anti-CTLA-4 agents such as ipilimumab and tremelimumab, was designed to activate antigen-presenting cells, enhance T-cell priming and memory, and selectively reduce intratumoral Treg, thereby remodeling the tumor microenvironment and enabling activity in immunologically "cold" tumors (27, 28). Additionally, the Fc domain of BOT was engineered to mitigate complement C1q binding, thereby reducing complement-mediated immune toxicities associated with conventional anti-CTLA-4 agents (27). When combined with balstilimab (BAL), an anti-PD-1 antibody pharmacologically comparable with approved PD-1 inhibitors

(29, 30), BOT + BAL has demonstrated antitumor immunity with deep and durable tumor responses across tumors classified as "cold" or treatment refractory (31), including MSS mCRC (as previously published; ref. 32), sarcomas (33), ovarian cancer (34), and ICI-refractory hepatocellular carcinoma (35) and melanoma (36).

We now report extended follow-up data from the C-800-01 trial on 123 patients with MSS mCRC NLM treated with BOT + BAL, including 37 patients previously exposed to available late-line therapies. Given that active liver metastases are associated with a uniquely immunosuppressive tumor microenvironment that can abrogate systemic antitumor immunity in an already "cold" disease (37, 38), we prospectively defined a cohort of patients with MSS mCRC who lacked active liver metastases to evaluate BOT + BAL safety and efficacy. In this analysis, "NLM" was defined as patients with definitively treated liver metastases or no history of liver metastases. Importantly, and as previously mentioned, patients with NLM have better prognoses than patients with active liver metastases (19). In this report, we provide extended follow-up of safety and efficacy data, including long-term survival outcomes, in an MSS mCRC NLM population.

Patients and Methods

Trial design and participants

C-800-01 (NCT03860272) was an open-label, phase Ib, multicenter trial evaluating the safety, tolerability, efficacy, and pharmacokinetic/pharmacodynamic profiles of BOT ± BAL. Patients with MSS mCRC NLM were enrolled and treated between May 11, 2020, and September 29, 2023, at 15 sites across the United States and the United Kingdom (now closed to enrollment). The trial design, dose escalation, and interim results from the MSS mCRC cohort have been previously reported (32). The prior report included 77 evaluable patients with MSS mCRC NLM at an earlier data cutoff; additional patients with MSS mCRC NLM have since been treated, comprising the total cohort with NLM, which is the subject of this report.

Comprehensive eligibility criteria are provided in the Supplementary Methods. Eligible patients were ≥18 years of age with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1, adequate organ function, and confirmed metastatic or locally advanced disease. Previous anti-PD-(L)1 ± anti-CTLA-4 was permitted, with no limit on prior lines of therapy. This report only included patients with NLM, defined as those with definitively treated liver metastases or no history of liver metastases. MSS/pMMR was tested per approved local standard testing [immunohistochemistry, polymerase chain reaction, and/or next-generation sequencing (NGS)]. The trial was conducted in compliance with the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice and was approved by the institutional review board at each institution, with all patients providing written informed consent.

Procedures

Patients enrolled in the dose-expansion phase received BOT 1 or 2 mg/kg intravenously once every 6 weeks + BAL 3 mg/kg intravenously every 2 weeks, both for up to 2 years or until disease progression or unacceptable toxicity. Patients were assigned to available open treatment cohorts through the study's operational

slot allocation and enrollment process, with cohort availability determined by safety monitoring committee-reviewed dose decisions.

Endpoints

The primary objective/endpoint was to assess safety and toxicity, including the occurrence of dose-limiting toxicities (DLT), during dose escalation. As previously reported, a maximum tolerated dose was not reached (NR), and no DLT occurred in the MSS mCRC cohort (32). Secondary endpoints included assessment of the frequency, severity, and duration of treatment-emergent adverse events (TEAE) according to the National Cancer Institute's Common Terminology Criteria for Adverse Events v5.0 (NCI CTCAE v5.0). Immune-mediated adverse events (imAE) were also assessed; imAE were medically adjudicated and defined as related to treatment, thought to have an immune mechanism, determined by the investigator to be immune related, and/or treated with systemic steroids (of any dose) and/or other immunosuppressants or with thyroid replacement hormones. imAE were identified from a prespecified list of preferred terms. Secondary efficacy endpoints included ORR, duration of response (DOR), disease control rate [DCR; defined as the best response of complete response (CR), partial response (PR), or stable disease (SD) at ≥ 6 weeks], and progression-free survival (PFS), per RECIST v1.1 based on investigator assessment. OS was an exploratory endpoint. The clinical benefit rate (CBR; defined as the best response of CR, PR, or SD at ≥ 24 weeks) was also assessed. An exploratory, post hoc subgroup analysis was conducted, which included patients previously exposed to available later-line therapies for MSS mCRC before enrollment (deemed as the "late line-exposed" subgroup; defined as ≥ 1 prior regimen of regorafenib, trifluridine/tipiracil $\pm$ bevacizumab, or fruquintinib). Patients who have progressed following these regimens have limited remaining treatment options and represent a population with historically poor outcomes. As such, this subgroup analysis was intended to evaluate a population with high unmet need in MSS mCRC and whether BOT + BAL had clinical activity in patients with highly treatment-refractory disease. Imaging was performed every 6 weeks (± 3 days) from the first dose.

Statistical analysis

The safety population (in which all analyses were conducted) included all patients who received ≥ 1 dose of the study drug. Safety endpoints were tabulated by dose level using descriptive statistics, and the severity of adverse events (AE) was graded using NCI CTCAE v5.0 whenever possible. Descriptive statistics were also used to summarize trial results (means, medians, ranges, and variability). Categorical variables were summarized by counts and percentages. For patients with a CR or PR, the DOR was summarized using Kaplan–Meier methods, as were PFS and OS for all patients. Median time to event(s) and 95% confidence interval (CI) for the median(s) were also provided. Missing efficacy or safety data were not imputed unless otherwise specified in the statistical analysis plan (SAP). Statistical analyses were performed using SAS software (RRID: SCR_008567; v9.4; SAS Institute Inc.). The protocol and SAP can be found in the Supplementary Materials.

Correlative studies

Correlative analyses were exploratory in nature and evaluated associations among PD-L1 expression (centrally assessed), tumor mutational burden (TMB), and treatment response. Detailed methodology is provided in the Supplementary Methods.

Results

Patients

The prior interim report of this cohort included 77 evaluable patients with MSS mCRC NLM (prior data cutoff: November 29, 2023; ref. 32). Here, we report findings from an additional 46 patients ($N = 123$) with extended follow-up, mature survival landmarks, and treatment-free survival characterization. As of the data cutoff for this report (December 13, 2025), 123 patients with MSS mCRC NLM were treated with BOT 1 mg/kg ($n = 62$) or 2 mg/kg ($n = 61$) every 6 weeks plus BAL 3 mg/kg every 2 weeks (Supplementary Fig. S1). The median number of BOT and BAL doses received was 2 (range, 1–17) and 6 (range, 1–52), respectively. The median follow-up was 20.2 months (range, 0.7–62.3). The median follow-up estimate via reverse Kaplan–Meier was 34.8 months (95% CI, 28.2–38.1); reverse Kaplan–Meier follow-up treats deaths as censored observations and provides an estimate of the potential follow-up time available for assessing long-term outcomes.

Demographics and baseline disease characteristics are provided in Table 1. The median age was 56 years (range, 25–82). Patients had received a median of 3 prior lines of therapy [range, 1–10; 67% ($n = 82$) had ≥ 3 prior lines]; 16% ($n = 20$) had previously treated liver metastases, 84% ($n = 103$) had no history of liver metastases, and 15% ($n = 18$) received prior anti-PD-(L)1 $\pm$ anti-CTLA-4. Fifty-six (46%) patients had an ECOG PS score of 0, and 67 (54%) had a score of 1. The median time from initial diagnosis and metastatic disease diagnosis to study treatment was 46 months (range, 6.1–208.1) and 33.9 months (range, 0.2–179.4), respectively. Patients had a high metastatic burden, with 69% having metastases at ≥ 2 sites and frequent lung (78%), lymph node (44%), and peritoneal (39%) involvement. Thirty-seven (30%) patients received ≥ 1 regimen of regorafenib, trifluridine/tipiracil $\pm$ bevacizumab, or fruquintinib. In patients with TMB data available by local clinical test ($n = 77$), 8% ($n = 6$) had TMB > 10 mutations/megabase (Mut/Mb), and none had TMB > 25 Mut/Mb. Of 113 patients with RAS data available, 67% had tumors with RAS mutation. A table describing study representativeness is provided in Supplementary Table S1.

Safety

No new safety signals were observed with extended follow-up ($N = 123$; safety population). All patients experienced any TEAE (grade ≥ 3 , 73%), and 113 (92%) patients experienced any treatment-related AE (TRAE; grade ≥ 3 , 41%). The most common TRAE (by preferred term) were diarrhea (39%; grade ≥ 3 , 8%), fatigue (37%; grade ≥ 3 , 2%), and pyrexia (24%; grade ≥ 3 , 3%; Table 2). Overall, 21 (17%) patients had TRAE (related to both BOT and BAL) leading to discontinuation of both BOT and BAL (reflects patients who discontinued all study treatment). There were no treatment-related deaths (no grade 5 TRAE).

imAE, which were treatment related, defined using criteria described in the Methods and analyzed using grouped preferred terms unless otherwise stated (see Supplementary Table S2), occurred in 72 (59%; grade 3, 29%; grade 4, 1%; no grade 5) patients. The most common was immune-mediated diarrhea/colitis (imDC; grouped term that included immune-mediated enterocolitis, colitis, diarrhea, and autoimmune colitis; $n = 51$, 41%; grade ≥ 3 , 15%). Other imAE occurred in $\leq 10\%$ of patients and included thyroid disorders (7%; grade ≥ 3 , 0%), pulmonary events (5%; grade ≥ 3 , 2%), and hepatitis (5%; grade ≥ 3 , 2%). There was only 1 grade 4 imAE (imDC; details in the supplement), which occurred in the BOT 2-mg/kg dose

Table 1. Demographics and baseline disease characteristics of all patients with MSS mCRC NLM (*N* = 123).

Characteristic	Overall (<i>N</i> = 123)	BOT 1 mg/kg + BAL (<i>n</i> = 62)	BOT 2 mg/kg + BAL (<i>n</i> = 61)
Age, median (range)	56 (25–82)	56 (35–81)	57 (25–82)
Sex, <i>n</i> (%)			
Male	63 (51)	32 (52)	31 (51)
ECOG PS, <i>n</i> (%)			
0	56 (46)	33 (53)	23 (38)
1	67 (54)	29 (47)	38 (62)
Primary site, <i>n</i> (%)			
Colon	81 (66)	37 (60)	44 (72)
Rectal	42 (34)	25 (40)	17 (28)
Time from initial cancer diagnosis to first dose of the study drug, months, median (range)	46.0 (6.1–208.1)	41.5 (6.1–208.1)	52.2 (9.5–181.2)
Time from metastatic disease to first dose of the study drug, months, median (range)	33.9 (0.2–179.4)	28.5 (0.2–104.6)	39.9 (5.4–179.4)
Target lesions SOD, mm, median (range)	61 (10–220)	71 (10–220)	53 (10–181)
Sites of metastases, <i>n</i> (%)			
≥2 metastatic sites	85 (69)	44 (71)	41 (67)
Lung metastases	96 (78)	50 (81)	46 (75)
Lymph node metastases	54 (44)	27 (44)	27 (44)
Peritoneal metastases	48 (39)	23 (37)	25 (41)
Liver metastases status, <i>n</i> (%) ^a			
Treated liver metastases	20 (16)	3 (5)	17 (28)
No liver metastases	103 (84)	59 (95)	44 (72)
Number of prior lines of therapy			
Median (range)	3 (1–10)	3 (1–8)	4 (1–10)
≥3, <i>n</i> (%)	82 (67)	34 (55)	48 (79)
≥4, <i>n</i> (%)	57 (46)	20 (32)	37 (61)
≥5, <i>n</i> (%)	34 (28)	9 (15)	25 (41)
≥6, <i>n</i> (%)	21 (17)	6 (10)	15 (25)
Prior types of therapy, <i>n</i> (%)			
Anti-PD-(L)1 ± anti-CTLA-4	18 (15)	6 (10)	12 (20)
≥1 regimen of regorafenib, trifluridine/tipiracil ± bevacizumab, or fruquintinib	37 (30)	12 (19)	25 (41)
Other characteristics			
MSS/pMMR, <i>n</i> (%)	123 (100)	62 (100)	61 (100)
TMB >10, Mut/Mb, <i>n/N</i> (%) ^{b,c}	6/77 (8)	4/41 (10)	2/36 (6)
TMB >25, Mut/Mb, <i>n/N</i> (%) ^{b,c}	0/77 (0)	0/41 (0)	0/36 (0)
RAS mutation, <i>n/N</i> (%) ^c	76/113 (67)	44/59 (75)	32/54 (59)
BRAF V600E mutation, <i>n/N</i> (%) ^c	1/60 (2)	1/23 (4)	0/37 (0)

Data cutoff: December 13, 2025.

Abbreviations: BRAF, v-Raf murine sarcoma viral oncogene homolog b; RAS, rat sarcoma virus; SOD, sum of the diameter.

^aAll patients had NLM, which was defined as patients with definitively treated liver metastases or no history of liver metastases.^bTMB per tumor-based local clinical test.^c*N* represents the number of patients with available data from local clinical test.

group. Hypophysitis occurred in 1 patient (grade 3; details in the supplement). imAE were dose dependent; both any-grade imAE and any-grade imDC occurred in fewer patients receiving BOT 1 mg/kg + BAL compared with BOT 2 mg/kg + BAL (Supplementary Table S2). Due to imAE, 33 (27%) patients temporarily interrupted and 42 (34%) patients discontinued 1 or both study drugs (BOT and/or BAL; patients may have discontinued 1 drug while continuing the other).

Tumor necrosis factor α (TNFα) inhibitors (e.g., infliximab) were used for imDC management, including in steroid-sensitive patients, to accelerate symptom resolution, reduce cumulative corticosteroid exposure, and enable safe retreatment (39). Per protocol, TNFα inhibition was recommended within 3 days of imDC symptom onset of any grade, including grade 1. Among the 51 patients who experienced imDC, 63% (*n* = 32/51) received combination systemic

steroids and TNFα inhibition, 25% (*n* = 13/51) received systemic steroids alone, and 10% (*n* = 5/51) received TNFα inhibition alone; 1 (2%; *n* = 1/51) patient did not receive immunosuppressive agents. Overall, 98% (*n* = 50/51) of imDC events resolved; the median time to resolution from imDC onset was 14 days (interquartile range, 7–27).

Efficacy

In this updated analysis (prior data cutoff: November 29, 2023; current data cutoff: December 13, 2025) with more patients (*N* = 123) and extended follow-up as previously noted, additional responders were identified; the confirmed ORR was 21% (26/123; 95% CI, 14–29), including 3 CR and 23 PR (Fig. 1A and B; Table 3; refs. 32, 40). Across each BOT dose, the efficacy was consistent [BOT 1 mg/kg + BAL: ORR, 21% (13/62); BOT 2 mg/kg + BAL: ORR, 21%

Table 2. Safety overview, including the most common treatment-related imAE and TRAE (occurred in ≥10% of patients with MSS mCRC NLM; *N* = 123).

<i>n</i> (%)	Overall (<i>N</i> = 123)		BOT 1 mg/kg + BAL (<i>n</i> = 62)		BOT 2 mg/kg + BAL (<i>n</i> = 61)	
Any TRAE	113 (92)		55 (89)		58 (95)	
Grade ≥3	51 (41)		22 (35)		29 (48)	
Leading to discontinuation of both BOT and BAL ^a	21 (17)		7 (11)		14 (23)	
Leading to death	0		0		0	
	Any grade	Grade ≥3	Any grade	Grade ≥3	Any grade	Grade ≥3
Any treatment-related imAE ^b	72 (59)	37 (30)	28 (45)	15 (24)	44 (72)	22 (36)
Most common (≥10%)						
Diarrhea/colitis ^c	51 (41)	19 (15)	17 (27)	6 (10)	34 (56)	13 (21)
Most common (≥10%) TRAE^d	Any grade	Grade ≥3	Any grade	Grade ≥3	Any grade	Grade ≥3^e
Diarrhea	48 (39)	10 (8)	27 (44)	3 (5)	21 (34)	7 (12)
Fatigue	46 (37)	2 (2)	23 (37)	1 (2)	23 (38)	1 (2)
Pyrexia	30 (24)	4 (3)	16 (26)	2 (3)	14 (23)	2 (3)
Decreased appetite	27 (22)	0	16 (26)	0	11 (18)	0
Rash maculopapular	27 (22)	2 (2)	14 (23)	1 (2)	13 (21)	1 (2)
Chills	26 (21)	0	9 (15)	0	17 (28)	0
Pruritus	26 (21)	0	13 (21)	0	13 (21)	0
Immune-mediated enterocolitis	24 (20)	10 (8)	5 (8)	3 (5)	19 (31)	7 (12)
Nausea	23 (19)	0	10 (16)	0	13 (21)	0
Colitis	22 (18)	6 (5)	10 (16)	3 (5)	12 (20)	3 (5)
ALT increased	21 (17)	3 (2)	12 (19)	2 (3)	9 (15)	1 (2)
Arthralgia	21 (17)	0	11 (18)	0	10 (16)	0
Anemia	18 (15)	1 (1)	9 (15)	1 (2)	9 (15)	0
AST increased	16 (13)	2 (2)	10 (16)	1 (2)	6 (10)	1 (2)
Headache	15 (12)	1 (1)	9 (15)	0	6 (10)	1 (2)
Myalgia	14 (11)	0	8 (13)	0	6 (10)	0
Rash	13 (11)	0	4 (7)	0	9 (15)	0
Blood ALP increased	11 (9)	0	4 (7)	0	7 (12)	0
Stomatitis	11 (9)	0	6 (10)	0	5 (8)	0


Data cutoff: December 13, 2025.

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

^aRelated to both BOT and BAL.^bimAE were medically adjudicated and defined as related to treatment, thought to have an immune mechanism, determined by the investigator to be immune related, and/or treated with systemic steroids (of any dose) and/or other immunosuppressants or with thyroid replacement hormones. imAE were identified from a prespecified list of preferred terms.^cIdentified events of “diarrhea/colitis” (grouped term) included the preferred terms of immune-mediated enterocolitis, colitis, diarrhea, and autoimmune colitis.^dPreferred terms. Multiple preferred terms may have occurred in 1 patient during a given event.^eAmong the TRAE in this table, there was only 1 grade 4 event (1 patient with grade 4 colitis in the BOT 2 mg/kg + BAL arm).

(13/61; **Table 3**; Supplementary Fig. S2]. Among responders (*n* = 26), the median number of BOT doses was 3 (range, 1–17), and the median number of BAL doses was 23 (range, 2–49). The median DOR was NR (95% CI, 7.3–NR; **Fig. 1C**), and DOR ranged from 1.9 to ≥37.4 months, with 10 responses ongoing at data cutoff. The DCR was 69% (85/123; 95% CI, 60–77), and the CBR was 28% (34/123; 95% CI, 20–36). The median PFS was 4.0 months (95% CI, 2.8–4.1), 12-month PFS was 23% (95% CI, 15–31), and 18-month PFS was 18% (95% CI, 11–26; **Fig. 2A**; **Table 3**). The median OS was 21.2 months (95% CI, 16.2–23.8), with 12-month, 24-month, and 36-month OS rates of 65% (95% CI, 55–72), 41% (95% CI, 32–50), and 33% (95% CI, 24–43), respectively (**Fig. 2B**; **Table 3**). At last follow-up, 21 (17%) patients were alive and off all therapy (Supplementary Fig. S3A), of whom 13 were responders. Treatment-free survival is shown in Supplementary Fig. S3B.

Efficacy in the exploratory, post hoc subgroup of patients previously exposed to available late-line therapies (*n* = 37; demographics in Supplementary Table S3) was similar to the overall population (**Fig. 3A and B**; Supplementary Table S4); the confirmed ORR was 22% (8/37; 95% CI, 10–38; including 1 CR and 7 PR). The median DOR was 16.6 months (95% CI, 1.9–NR; **Fig. 3C**); DOR ranged from 1.9 to ≥24.3 months, with 2 responses ongoing at data cutoff. The DCR was 70% (26/37; 95% CI, 53–84), and the CBR was 27% (10/37; 95% CI, 14–44). The median PFS was 4.1 months (95% CI, 2.8–6.4), 12-month PFS was 20% (95% CI, 9–36), and 18-month PFS was 17% (95% CI, 6–32; Supplementary Fig. S4A; Supplementary Table S4). The median OS was 16.2 months (95% CI, 9.7–31.3), with 12-month, 24-month, and 36-month OS rates of 54% (95% CI, 37–68), 35% (95% CI, 19–51), and 30% (95% CI, 15–46), respectively (Supplementary Fig. S4B; Supplementary Table S4).

**Figure 1.**

(A) Best overall response, (B) response over time, and (C) DOR in the overall population of patients with MSS mCRC NLM receiving either dose of BOT + BAL. Data cutoff: December 13, 2025. ^a $n = 121$ patients with percent change from baseline in tumor measurement. ^bResponse data for this patient were corrected because of a documented database error identified after database lock; correction reflects validated source data.

Correlative biomarker studies

Responses to BOT + BAL were observed in tumors with low TMB and PD-L1 combined positive score (CPS) of 0 points (Supplementary

Table S5). There was no significant difference in TMB between responders (patients with CR/PR) and nonresponders (patients with SD/progressive disease; $P = 0.94$), and TMB did not correlate with best

Table 3. Efficacy overview in all patients with MSS mCRC NLM ($N = 123$).

	Overall ($N = 123$)	BOT 1 mg/kg + BAL ($n = 62$)	BOT 2 mg/kg + BAL ($n = 61$)
ORR, n (%)	26 (21)	13 (21)	13 (21)
95% CI	14–29	12–33	12–34
BOR, n (%)			
CR	3 (2)	0	3 (5)
PR	23 (19)	13 (21)	10 (16)
SD	59 (48)	26 (42)	33 (54)
PD	34 (28)	21 (34)	13 (21)
NE	4 (3)	2 (3)	2 (3)
Median DOR, months (95% CI)	NR (7.3–NR)	12.9 (3.2–NR)	NR (7.3–NR)
DCR at ≥ 6 weeks, n (%)	85 (69)	39 (63)	46 (75)
95% CI	60–77	50–75	63–86
CBR at ≥ 24 weeks, n (%)	34 (28)	19 (31)	15 (25)
95% CI	20–36	20–44	15–37
Median PFS, months (95% CI)	4.0 (2.8–4.1)	3.3 (2.7–4.4)	4.1 (2.8–5.1)
12-month PFS, % (95% CI)	23 (15–31)	24 (14–36)	21 (11–33)
18-month PFS, % (95% CI)	18 (11–26)	20 (10–31)	17 (8–29)
Median OS, months (95% CI)	21.2 (16.2–23.8)	20.2 (11.5–24.4)	21.2 (13.3–31.3)
18-month OS, % (95% CI)	57 (48–65)	55 (42–66)	59 (46–71)
24-month OS, % (95% CI)	41 (32–50)	39 (26–51)	43 (30–56)
30-month OS, % (95% CI)	37 (28–46)	37 (24–49)	38 (25–51)
36-month OS, % (95% CI)	33 (24–43)	37 (24–49)	32 (19–46)
Median follow-up, months (range)	20.2 (0.7–62.3)	19.8 (0.7–62.3)	20.7 (2.3–50.0)
Median follow-up (reverse KM), months (95% CI)	34.8 (28.2–38.1)	28.8 (27.6–36.2)	41.4 (28.4–43.2)

Data cutoff: December 13, 2025.

Abbreviations: BOR, best overall response; KM, Kaplan–Meier; NE, not evaluable; PD, progressive disease.

percent change in target lesions from baseline ($R^2 = 0.02$; $P = 0.46$; Supplementary Fig. S5A and S5B). PD-L1 CPS did not differ significantly between responders and nonresponders ($P = 0.99$), nor did it correlate with best percent change in target lesions from baseline ($R^2 = 0.02$; $P = 0.39$; Supplementary Fig. S5C and S5D). Of the responders with clinical tissue-based NGS data available ($n = 18$), none had a TMB >13 nor a *POLE* mutation associated with hypermutation. Thus, these conventional ICI biomarkers did not reliably differentiate responders from nonresponders to BOT + BAL.


Discussion

With mature follow-up, BOT + BAL resulted in durable and clinically meaningful outcomes among this expanded cohort of 123 patients with treatment-refractory MSS mCRC NLM, including 21% ORR, 28% 24-week CBR, and a median OS of 21.2 months. Two thirds of patients had received ≥ 3 prior therapy lines, 15% had prior exposure to anti-PD-(L)1 $\pm$ anti-CTLA-4, and many had long-standing metastatic disease with a substantial burden of metastatic involvement at study entry. Additionally, 30% of patients had prior exposure to available late-line therapies (≥ 1 regimen of regorafenib, trifluridine/tipiracil $\pm$ bevacizumab, or fruquintinib), and clinical activity in this exploratory, post hoc subgroup was comparable with the overall population. The sustained activity in this exploratory, post hoc subgroup exposed to available late-line therapies is particularly notable, as the efficacy of conventional cytotoxic and targeted therapies typically diminishes with subsequent lines of treatment, in part because more effective options are used earlier (41). These long-term outcomes are consistent with the prior NLM cohort analysis (ORR, 20%; median OS, 20.9 months; ref. 40) and, with extended follow-up, further substantiate the durable and

sustained clinical benefit with BOT + BAL. No new safety signals emerged with extended follow-up, and findings were consistent with previous reports (32, 40).

These results with BOT + BAL are clinically meaningful given the substantial unmet need for patients with MSS mCRC, particularly after progression on doublet/triplet chemotherapy with anti-VEGF or anti-EGFR biologics (6–8, 10). Additionally, although patients with NLM have better prognoses than patients with active liver metastases, clinical benefit with currently available salvage therapies remains limited with NLM (19). In the salvage setting among patients with NLM, regorafenib, trifluridine/tipiracil $\pm$ bevacizumab, and fruquintinib evaluated in phase III studies have demonstrated ORR of 3% to 8% and median OS of approximately 12 to 14 months (17–19). Furthermore, although recent, pivotal phase III results with zanzalitinib (multitargeted tyrosine kinase inhibitor) + atezolizumab (anti-PD-L1) demonstrated a statistically significant survival improvement versus regorafenib in patients with NLM (interim analysis: median OS, 15.9 vs. 12.7 months), the survival improvement was clinically modest (42). Among all-comers, there was no meaningful increase in ORR (4% vs. 1%) and no evidence of a meaningful, durable survival plateau with zanzalitinib + atezolizumab (42). Contextualizing these data, durable disease control and long-term survival remain rare after standard therapies in patients with NLM, highlighting the persistent unmet need for more effective novel treatments. Importantly, none of these therapies involve ICI alone, and all standard lines of treatment include chemotherapy or targeted therapy. Thus, BOT + BAL stands out as a mature, ICI-only treatment paradigm in MSS mCRC NLM.

Against this historical backdrop of limited survival in treatment-refractory MSS mCRC NLM, BOT + BAL demonstrated sustained long-term benefit, with 24-month and 36-month OS rates of 41%

**Figure 2.**

(A) PFS and (B) OS in the overall population of patients with MSS mCRC NLM receiving either dose of BOT + BAL. Data cutoff: December 13, 2025.

and 33%, respectively. The maturity of the dataset, reflected by a reverse Kaplan–Meier median follow-up estimate of 34.8 months (a measure of potential follow-up that is less influenced by early deaths) and continued patient observation beyond 24 and 36 months, supports the robustness of these long-term survival findings and the characterization of a durable survival tail. Durable survival in MSS mCRC NLM remains uncommon with currently available therapies, as Kaplan–Meier curves show that few patients remain alive at 18 months with very few at risk by 24 months (17–19). Although the median PFS in this study was modest (4.0 months), landmark PFS rates provide additional context with regard to the disease control demonstrated among the subset of patients who remained progression free beyond 1 year, rather than reflecting the experience of the overall study population. Notably, the 12-month and 18-month PFS rates with BOT + BAL were 23% and 18%, respectively, indicating that approximately 20% of patients remained progression free beyond 1 year despite many receiving therapy in the ≥ 3 -line setting. With regorafenib, trifluridine/tipiracil, and fruquintinib, few patients with NLM remain progression free beyond 1 year, with 18-month PFS rates uniformly approaching zero (17–19). Importantly, cross-trial comparisons should be interpreted with caution, given differences in study design


and patient populations; thus, these observations should be viewed as hypothesis generating rather than definitive.

The safety profile of BOT + BAL remained consistent with prior reports (32, 40), with no new safety signals with extended follow-up. imAE were dose dependent, with lower rates of any-grade imAE and imDC observed at the BOT 1 mg/kg + BAL dose, supporting its selection for phase III investigation. Consistent with evolving best practices for ICI-related imDC management (39, 43, 44), early integration of steroid-sparing agents, including TNF α inhibitors, was incorporated in steroid-responsive cases. This approach minimized prolonged high-dose corticosteroid exposure and contributed to a manageable, largely resolvable (98% in this cohort) imDC toxicity profile. Severe immune-related toxicity was infrequent, with only a single grade 4 imAE (imDC that resolved completely) and no treatment-related deaths.

Per trial design, patients could receive BOT (administered every 6 weeks) for up to 2 years; however, the median number of BOT doses administered was 2 (range, 1–17). This is consistent with clinical precedent from first-generation/conventional anti-CTLA-4 therapies combined with anti-PD-(L)1 agents, including ipilimumab (historically administered as a short induction course) and tremelimumab (administered as a single priming dose in the

Figure 3.

(A) Best overall response, (B) response over time, and (C) DOR in patients with MSS mCRC NLM previously exposed to available late-line therapies^a who received either dose of BOT + BAL. Data cutoff: December 13, 2025. ^aReceived ≥ 1 prior regimen of regorafenib, trifluridine/tipiracil $\pm$ bevacizumab, or fruquintinib. This was an exploratory, post hoc subgroup analysis.



STRIDE regimen), which demonstrated that prolonged CTLA-4 blockade is not required to generate durable anticancer immunity (20, 45, 46). These observations support the hypothesis that CTLA-4 blockade primarily drives early immune priming and expansion of antitumor T-cell responses, whereas continued PD-(L)1 blockade supports maintenance of long-term antitumor immunity (47).

Consistent with this mechanism, durable responses and prolonged survival were observed despite limited BOT exposure (median of 2 BOT doses), with 41% and 33% of patients alive at 2 and 3 years, respectively.

Critically, extended follow-up continued to demonstrate consistent efficacy across both BOT doses (ORR of 21% with both BOT

1 and 2 mg/kg), with lower rates of immune-mediated toxicity at BOT 1 mg/kg + BAL. These findings are also consistent with results from a randomized phase II trial in MSS mCRC NLM, in which BOT 75 mg + BAL demonstrated a confirmed ORR of 19% with similar safety observations (48). Together, these data support an improved benefit–risk profile without loss of efficacy at the lower BOT dose, justifying selection of BOT 75 mg as the fixed dose for further evaluation in future clinical trials.

BOT + BAL demonstrated clinical activity independent of standard immunotherapy biomarkers, including TMB and PD-L1 expression, supporting the FcγR-dependent mechanism involving myeloid reprogramming and T-cell priming rather than tumor-intrinsic immunogenicity (28). This suggests that BOT + BAL activity extends beyond conventional ICI biomarker–selected subpopulations in MSS mCRC and that TMB and PD-L1 do not reliably distinguish responders from nonresponders. Accordingly, predictive biomarker development will require integrative translational approaches that capture tumor microenvironment architecture and systemic immune context rather than tumor-intrinsic features alone. Exploratory analyses in other BOT + BAL–treated populations, including ovarian cancer, sarcomas, and a large pan-tumor cohort ($n = 341$), have begun to identify predictive features and provide further mechanistic insights (33, 34, 49).

This study had several limitations. This was a nonrandomized, open-label phase Ib cohort without a control arm, limiting cross-trial comparisons and definitive efficacy conclusions. Restriction to patients with NLM, although biologically justified, may have enriched for patients with more favorable prognoses and limited generalizability to those with active liver metastases. In addition, the exploratory, post hoc subgroup analysis was not powered for formal comparison and should be considered descriptive. Biomarker analyses were limited by data availability. Ongoing randomized studies are needed to confirm clinical benefit and better define patients most likely to derive durable benefit from BOT + BAL.

In summary, BOT + BAL demonstrated clinically meaningful and durable antitumor activity in heavily pretreated patients with MSS mCRC NLM, a population that has a more favorable prognosis than patients with active liver metastases but in whom durable survival beyond 18 months remains uncommon. With a confirmed ORR of 21%, sustained survival beyond 2 and 3 years, consistent activity in heavily pretreated patients, and a manageable safety profile, this regimen represents a potentially important advance in the treatment of immunologically “cold” MSS mCRC NLM. These findings underscore the potential of BOT, an Fc-enhanced anti–CTLA-4 antibody, combined with PD-1 blockade (BOT + BAL), to generate meaningful antitumor activity in immunologically “cold” and ICI-refractory tumors and support phase III evaluation.

Data Availability

Individual patient clinical data will be deidentified in addition to molecular data supporting the findings presented herein, all of which will be made available for academic use upon reasonable written request, subject to informed consent constraints. Any researchers interested in accessing data from this article should submit a request to the corresponding author (Benjamin Schlechter; benjamin_schlechter@dfci.harvard.edu), in addition to a signed data transfer agreement. Access will be granted only if terms are agreed upon in the data transfer agreement, including provisions that data can only be used for research purposes, must maintain patient confidentiality, and other information, all for the duration of the agreement. All materials, data, and protocols described in this article will be made available upon request, if the request is made within 6 years of publication of this

article. Each request will be reviewed individually, with responses provided within a maximum of 2 weeks.

Authors' Disclosures

B.L. Schlechter reports personal fees and other support from Agenus Inc. during the conduct of the study, as well as personal fees from AstraZeneca, Lyell, and Larkspur outside the submitted work. M.G. Fakih reports personal fees from AbbVie, Inc., Adagene Inc., Astellas Pharma, Bayer Corporation, Bristol Myers Squibb, Delcath Systems, Inc., Exelixis, Inc., GlaxoSmithKline, Iterion Therapeutics, Inc., Janssen Research & Development, Merck, Merus N.V., Microbial Machines, Mirati Therapeutics, Inc., Revolution Medicines, Inc., Roche/Genentech, Servier Affaires Medicales, Summit Therapeutics Inc., Taiho Oncology, Tempus, Tonus Medicines Inc., and Xilio Therapeutics outside the submitted work. A.M. Tsimberidou reports grants from Agenus Inc., Immatics, Tempus, ANAVEON, Pilatus Biosciences, MacroGenics, 7 Hills Pharma, Cancer Prevention and Research Institute of Texas (CPRIT), NCI, Orion Biosciences, Novocure, and Vividion Therapeutics; grants and personal fees from OBI Pharma; and personal fees from BrYet and NEX-1 during the conduct of the study. A.J. Bullock reports grants from Agenus Inc. during the conduct of the study; grants from Pfizer, AstraZeneca, Panavance Therapeutics, EXACT Therapeutics, and Geistlich Pharma; and grants and personal fees from Sirtex outside the submitted work. A. Pimentel reports other support from Agenus Inc. during the conduct of the study. S. Sharma reports other support from Black Canyon Bio, Stingray Therapeutics, Bonneville Bio, and Iterion Therapeutics, Inc. outside the submitted work. H.-J. Lenz reports other support from Bristol Myers Squibb, 3T Biosciences, Adagene, GlaxoSmithKline, and BioNTech during the conduct of the study. M.S. Gordon reports grants and other support from Agenus Inc. during the conduct of the study; other support from Sphinx Health Solutions, Remepy, and Revolution Medicines, Inc.; and personal fees from Imaging Endpoints outside the submitted work. G.K. Abou-Alfa reports grants from Agenus Inc.; personal fees from Agenus Inc. during the conduct of the study; and grants from AbbVie, Inc., Amgen, Arcus, AstraZeneca, Atara Biotherapeutics, BeiGene, BioNTech, Bristol Myers Squibb, Cohere Oncology, Digestive Care, Inc., Elicio Therapeutics, Genentech/Roche, Helsinn, Incyte, J-Pharma, Revolution Medicines, Inc., Tango Therapeutics, and Yiviva; and personal fees from AbbVie, Inc., Ability Pharma, Alligator Bioscience, Amgen, Astellas Pharma, Arcus, AstraZeneca, Autem Therapeutics, Berry Genomics, BioNTech, Bristol Myers Squibb, Boehringer Ingelheim, FibroGen, Genentech/Roche, Ikena Oncology, Immuneering, Ipsen, J-Pharma, Merck, Merus, MOMA Therapeutics, Neogene, Novartis, Pfizer, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Servier, Syros Pharmaceuticals, Tango Therapeutics, Tempus, VECTOR Pharma, and Yiviva outside the submitted work. T.U. Marron reports personal fees from EMD Serono, AbbVie, Inc., Merck, Nature's Toolbox, EvolveImmune Therapeutics, Tubulis, AN2 Therapeutics, Caris Life Sciences, TATUM Bioscience, GE Healthcare, Galvanize Therapeutics, Pheast Therapeutics, Astellas Pharma, Boehringer Ingelheim, and Bayer Corporation outside the submitted work. R.W. Lentz reports other support from Natera and personal fees from KAHN Bio outside the submitted work. W. Messersmith reports other support from Agenus Inc. during the conduct of the study. I. Chau reports grants from Agenus Inc. during the conduct of the study, as well as personal fees and nonfinancial support from Bristol Myers Squibb, Takeda Pharmaceuticals, and Jazz Pharmaceuticals, personal fees from Astellas Pharma, BioNTech, Novartis, BeiGene, Gilead Sciences, Revolution Medicines, Inc., Merck Serono, Pfizer, Daiichi Sankyo, Servier, Roche, AstraZeneca, and Zuellig Pharma, and grants from Eli Lilly and Company outside the submitted work. B. Bockorny reports grants from Agenus Inc. during the conduct of the study, as well as other support from Enliven, Blueprint Medicines, SpringWorks Therapeutics, NIX10, and Rango outside the submitted work. D. Chand reports other support from Agenus Inc. outside the submitted work, as well as a patent for WO2025042997A1 related to Methods of Treating Colorectal Cancer Using a Combination of a CTLA-4 Inhibitor and a PD-1 Inhibitor and a patent for WO2024097200A1 related to Methods of Treating Colorectal Cancer Using an Anti-CTLA4 Antibody pending. M. Avagyan reports other support from Agenus Inc. outside the submitted work. J.E. Grossman reports personal fees, nonfinancial support, and other support from Agenus Inc. during the conduct of the study; personal fees and other support from Agenus Inc. and Moderna, Inc. outside the submitted work; and a patent for Methods of Treating Colorectal Cancer Using an Anti-CTLA4 Antibody pending and a patent for Methods of Treating Pancreatic Cancer Using an Anti-CTLA4 Antibody pending. S.J. O'Day reports other support from Agenus Inc. outside the submitted work. A.B. El-Khoueiry reports grants from Agenus Inc. during the conduct of the study; grants and personal fees from AstraZeneca; personal fees from Bristol Myers Squibb, Roche/Genentech, Eisai, Exelixis,

Inc., Elevar Therapeutics, Quriert, Jazz Pharmaceuticals, Johnson & Johnson, Daiichi Sankyo, Servier, Terumo, Merck, and AbbVie, Inc.; and grants from Astex Pharmaceuticals, Fulgent Pharma, and Auransa outside the submitted work. N.H. Segal reports personal fees from Inhibrx, Boehringer Ingelheim, Gilead Sciences, 3T Biosciences, and Astellas Pharma; grants and personal fees from Regeneron Pharmaceuticals, Pfizer, and Agenus Inc.; and grants from Roche/Genentech, Merck, Bristol Myers Squibb, AstraZeneca, and Immunocore Holdings during the conduct of the study. No disclosures were reported by the other authors.

Authors' Contributions

B.L. Schlechter: Conceptualization, data curation, supervision, investigation, writing—original draft, writing—review and editing. **M.G. Fakih:** Conceptualization, data curation, investigation, writing—original draft, writing—review and editing. **A.M. Tsimberidou:** Data curation, investigation, writing—original draft, writing—review and editing. **A.J. Bullock:** Data curation, investigation, writing—review and editing. **A. Pimentel:** Data curation, investigation, writing—review and editing. **S. Sharma:** Data curation, investigation, writing—review and editing. **H.-J. Lentz:** Data curation, investigation, writing—review and editing. **M.S. Gordon:** Data curation, investigation, writing—review and editing. **G.K. Abou-Alfa:** Data curation, investigation, writing—review and editing. **T.U. Marron:** Data curation, investigation, writing—review and editing. **R.W. Lentz:** Data curation, investigation, writing—review and editing. **W. Messersmith:** Data curation, investigation, writing—review and editing. **I. Chau:** Data curation, investigation, writing—review and editing. **B. Bockorny:** Data curation, investigation, writing—review and editing. **D. Chand:** Conceptualization, investigation, writing—review and editing. **M. Avagyan:** Data curation, formal analysis, methodology, writing—review and editing. **W. Wu:** Data

curation, formal analysis, methodology, writing—review and editing. **B. Johnson:** Conceptualization, investigation, writing—review and editing. **J.E. Grossman:** Conceptualization, investigation, writing—review and editing. **S.J. O'Day:** Conceptualization, investigation, writing—review and editing. **A.B. El-Khoueiry:** Data curation, investigation, writing—original draft, writing—review and editing. **N.H. Segal:** Data curation, investigation, writing—original draft, writing—review and editing.

Acknowledgments

The authors are grateful to the patients who participated in this trial and their families. The authors also thank Amanda Agazio, PhD, CMPP, and Ellie Manca, MPH (Agenus Inc.) for editorial assistance in the preparation of this manuscript; Cara Constance, PhD, BSN, RN (Agenus Inc.), for interpretation and acquisition of clinical data; Chloe Delepine, PhD; Sean Bourdelais, MS; and Bishnu Joshi, PhD (Agenus Inc.), for interpretation and acquisition of biomarker data; Tyler Curiel, MD, MPH, for his insights when developing the C-800-01 trial; and Richard Goldberg, MD, for clinical insights and contributions to interpretation of the study findings. Agenus Inc. supplied the drugs and partook in the design, conduct, analysis, and reporting of the trial. This study was funded by Agenus Inc.

Note

Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Received May 1, 2026; revised June 30, 2026; accepted August 19, 2026; posted first August 28, 2026.

References

- American Cancer Society. Global cancer facts & figures, 5th ed. Atlanta (GA): American Cancer Society; 2024.
- Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. *CA Cancer J Clin* 2025;75:10–45. <https://doi.org/10.3322/caac.21871>.
- Siegel RL, Wagle NS, Jemal A. Leading cancer deaths in people younger than 50 years. *JAMA* 2026;335:632–4. <https://doi.org/10.1001/jama.2025.25467>.
- Buchler T. Microsatellite instability and metastatic colorectal cancer - a clinical perspective. *Front Oncol* 2022;12:888181. <https://doi.org/10.3389/fonc.2022.888181>.
- Guyen DC, Kavgaci G, Erul E, Syed MP, Magge T, Saeed A, et al. The efficacy of immune checkpoint inhibitors in microsatellite stable colorectal cancer: a systematic review. *Oncologist* 2024;29:e580–600. <https://doi.org/10.1093/oncolo/oyae013>.
- Hoang T, Sohn DK, Kim BC, Cha Y, Kim J. Efficacy and safety of systemic treatments among colorectal cancer patients: a network meta-analysis of randomized controlled trials. *Front Oncol* 2021;11:756214. <https://doi.org/10.3389/fonc.2021.756214>.
- Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004;350:2335–42. <https://doi.org/10.1056/NEJMoa032691>.
- Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. *N Engl J Med* 2014;371:1609–18. <https://doi.org/10.1056/NEJMoa1403108>.
- Saltz LB, Cox JV, Blance C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. *N Engl J Med* 2000;343:905–14. <https://doi.org/10.1056/nejm200009283431302>.
- Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009;360:1408–17. <https://doi.org/10.1056/NEJMoa0805019>.
- Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. *Lancet* 2023;402:41–53. [https://doi.org/10.1016/s0140-6736\(23\)00772-9](https://doi.org/10.1016/s0140-6736(23)00772-9).
- Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013;381:303–12. [https://doi.org/10.1016/s0140-6736\(12\)61900-x](https://doi.org/10.1016/s0140-6736(12)61900-x).
- Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N Engl J Med* 2015;372:1909–19. <https://doi.org/10.1056/NEJMoa1414325>.
- Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. *N Engl J Med* 2023;388:1657–67. <https://doi.org/10.1056/NEJMoa2214963>.
- Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2015;16:619–29. [https://doi.org/10.1016/s1470-2045\(15\)70156-7](https://doi.org/10.1016/s1470-2045(15)70156-7).
- Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. *JAMA* 2018;319:2486–96. <https://doi.org/10.1001/jama.2018.7855>.
- Garcia-Carbonero R, Dasari A, Eng C, Tabernero J, Yoshino T, Hochster H, et al. Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer with and without liver metastasis: a subgroup analysis of the phase 3 FRESCO-2 trial. In: Poster presented at European Society for Medical Oncology 2024 Congress Poster 520P; Barcelona, Spain.
- Tabernero J, Prager GW, Taieb J, Calleja E, Liu M, Amellal N, et al. Impact of colorectal liver metastases (CRLM) in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in the phase 3 SUNLIGHT trial. In: Poster presented at American Society for Clinical Oncology Annual Meeting 2024 Poster 3584; Chicago, IL.
- Cohen R, Raeisi M, Chibaudel B, Shi Q, Yoshino T, Zalberg JR, et al. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: an ARCAD pooled analysis. *Eur J Cancer* 2024;207:114160. <https://doi.org/10.1016/j.ejca.2024.114160>.
- Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med* 2025;392:11–22. <https://doi.org/10.1056/NEJMoa2407417>.
- Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III

- melanoma. *N Engl J Med* 2024;391:1696–708. <https://doi.org/10.1056/NEJMoa2402604>.
22. André T, Elez E, Lenz HJ, Jensen LH, Toucheffu Y, Van Cutsem E, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. *Lancet* 2025;405:383–95. [https://doi.org/10.1016/s0140-6736\(24\)02848-4](https://doi.org/10.1016/s0140-6736(24)02848-4).
 23. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. *N Engl J Med* 2020;383:2207–18. <https://doi.org/10.1056/NEJMoa2017699>.
 24. Overman MJ, Kopetz S, McDermott RS, Leach J, Leonardi S, Lenz HJ, et al. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. In: Oral presentation at the American Society of Clinical Oncology Presentation #3501. Chicago, IL; 2016.
 25. Chen EX, Jonker DJ, Loree JM, Kennecke HF, Berry SR, Couture F, et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian cancer trials group CO. 26 study. *JAMA Oncol* 2020;6:831–8. <https://doi.org/10.1001/jamaoncol.2020.0910>.
 26. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. *Nat Med* 2018;24:541–50. <https://doi.org/10.1038/s41591-018-0014-x>.
 27. Chand D, Savitsky DA, Krishnan S, Mednick G, Delepine C, Garcia-Broncano P, et al. Botensilimab, an fc-enhanced anti-CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy. *Cancer Discov* 2024;14:2407–29. <https://doi.org/10.1158/2159-8290.Cd-24-0190>.
 28. Waight JD, Chand D, Dietrich S, Gombos R, Horn T, Gonzalez AM, et al. Selective FcγR Co-engagement on APCs modulates the activity of therapeutic antibodies targeting T cell antigens. *Cancer Cell* 2018;33:1033–47.e5. <https://doi.org/10.1016/j.ccell.2018.05.005>.
 29. O'Malley DM, Oaknin A, Monk BJ, Selle F, Rojas C, Gladieff L, et al. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. *Gynecol Oncol* 2021;163:274–80. <https://doi.org/10.1016/j.ygyno.2021.08.018>.
 30. O'Malley DM, Neffa M, Monk BJ, Melkadze T, Huang M, Kryzhanivska A, et al. Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study. *J Clin Oncol* 2022;40:762–71. <https://doi.org/10.1200/jco.21.02067>.
 31. Gordon MS, Tsimberidou AM, Schlechter BL, Wilky BA, Fakih MG, Bullock AJ, et al. Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors. In: Oral Presentation at the European Society for Medical Oncology 2025 Annual Meeting Presentation #1517MO; Berlin, Germany.
 32. Bullock AJ, Schlechter BL, Fakih MG, Tsimberidou AM, Grossman JE, Gordon MS, et al. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. *Nat Med* 2024;30:2558–67. <https://doi.org/10.1038/s41591-024-03083-7>.
 33. Wilky BA, Schwartz GK, Gordon MS, El-Khoueiry AB, Bullock AJ, Henick B, et al. Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with relapsed/refractory metastatic sarcomas. *J Clin Oncol* 2025;43:1358–68. <https://doi.org/10.1200/JCO-24-02524>.
 34. Porter R, Bockorny B, Corr BR, Mahadevan D, Wilky BA, El-Khoueiry AB, et al. Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer. *J Immunother Cancer* 2025;13:e013222. <https://doi.org/10.1136/jitc-2025-013222>.
 35. El-Khoueiry AB, Lieu CH, Abou-Alfa GK, Tsimberidou AM, Mahadevan D, Hanna DL, et al. A phase 1b study of botensilimab and balstilimab in treatment-refractory hepatocellular carcinoma. *Liver Cancer* 2026. [Epub ahead of print]. <https://doi.org/10.1159/000551630>.
 36. Atkins MB, Azambuja AA, Robert C, Dummer R, Lebbé C, Nathan PD, et al. Botensilimab ± balstilimab in patients with advanced cutaneous melanoma refractory/resistant to anti-PD-(L)1 ± CTLA-4: a phase 2 trial. Poster #259. In: Poster presentation at the 2026 American Society of Clinical Oncology. Chicago, IL.
 37. Sathe A, Mason K, Grimes SM, Zhou Z, Lau BT, Bai X, et al. Colorectal cancer metastases in the liver establish immunosuppressive spatial networking between tumor-associated SPP1+ macrophages and fibroblasts. *Clin Cancer Res* 2023;29:244–60. <https://doi.org/10.1158/1078-0432.Ccr-22-2041>.
 38. Liu S, Zhang Z, Wang Z, Liu C, Liang G, Xu T, et al. SPP1 drives colorectal cancer liver metastasis and immunotherapy resistance by stimulating CXCL12 production in cancer-associated fibroblasts. *Cancer Res* 2026;86:58–79. <https://doi.org/10.1158/0008-5472.Can-24-4916>.
 39. Faleck DM, Dougan M, Tello M, Grossman JE, Moss AC, Postow MA. Accelerating the evolution of immune-related enterocolitis management. *J Clin Oncol* 2023;41:3110–5. <https://doi.org/10.1200/jco.22.02914>.
 40. Schlechter BL, Fakih MG, Tsimberidou AM, Bullock AJ, Pimentel A, Sharma S, et al. Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite stable colorectal cancer and no active liver metastases. In: Poster presented at the European Society for Medical Oncology Gastrointestinal Cancers Symposium 2025 Poster 8P; Barcelona, Spain.
 41. Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. *Ther Adv Med Oncol* 2016;8:57–84. <https://doi.org/10.1177/1758834015614530>.
 42. Hecht JR, Park YS, Tabernero J, Lee MA, Lee S, Virgili AC, et al. Zanzalitinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STEL-LAR-303): a randomised, open-label, phase 3 trial. *Lancet* 2025;406:2360–70. [https://doi.org/10.1016/s0140-6736\(25\)0025-2](https://doi.org/10.1016/s0140-6736(25)0025-2).
 43. Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. *J Immunother Cancer* 2019;7:93. <https://doi.org/10.1186/s40425-019-0577-1>.
 44. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL Jr, Abdel-Wahab N, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. *J Immunother Cancer* 2018;6:103. <https://doi.org/10.1186/s40425-018-0412-0>.
 45. Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, et al. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. *J Hepatol* 2025;83:899–908. <https://doi.org/10.1016/j.jhep.2025.03.033>.
 46. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. *J Clin Oncol* 2015;33:1889–94. <https://doi.org/10.1200/jco.2014.56.2736>.
 47. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. *Cancer Discov* 2018;8:1069–86. <https://doi.org/10.1158/2159-8290.Cd-18-0367>.
 48. Fakih MG, Segal NH, Schlechter BL, André T, Pietrantonio F, Johnson B, et al. Preliminary results from a randomized, open-label, phase 2 study of botensilimab with or without balstilimab in refractory microsatellite stable metastatic colorectal cancer with no liver metastases. In: Oral Presentation at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium Abstract 23; San Francisco, CA.
 49. Delepine C, Bourdelais S, Mednick G, Keith JG, Driscoll E, Rozen A, et al. Systemic and tumor-microenvironment inflammation shape outcomes in patients with immunologically cold, treatment-refractory tumors treated with fc-enhanced anti-CTLA-4 botensilimab. In: Poster presented at the Annual American Association for Cancer Research Immuno-Oncology Conference Poster B036. Los Angeles, CA.